The mechanisms of lung carcinogenesis are not fully understood. Not all smokers develop lung cancer, indicating that genetic variations and other environmental factors may play an important role in its development. The human glutathione S-transferases (GSTs) have been associated with an increased risk of lung cancer. Glutathione S-transferases are phase II biotransformation enzymes that play a role in detoxifying a wide range of exogenous agents including carcinogens but also anticarcinogenic drugs.
Methods
We assessed the effect of allelic deletions in the GSTM1 and GSTT1 genotypes on lung cancer overall survival through a systematic review of the scientific literature after applying predefined inclusion and exclusion criteria.
Results
Most of the included studies found no effect or a tendency to worse survival for individuals with deletion of GSTs.
Conclusions
Further studies are necessary to understand the magnitude of the effect of the deletion of both genes on lung cancer survival.
SiegelR.L., MillerK.D., JemalA.Cancer statistics, 2016. CA Cancer J Clin.2016; 66(1): 7–30.
2.
RoyS.Herbst, John V. Heymach, Scott M. Lippman. Lung Cancer. J Med.2008; 359: 1367–1380.
3.
NielsenL.S., BælumJ., RasmussenJ.Occupational asbestos exposure and lung cancera systematic review of the literature. Arch Environ Occup Health.2014; 69(4): 191–206.
4.
LuqmanM., JavedM.M., DaudS., RaheemN., AhmadJ., KhanA.U.Risk factors for lung cancer in the Pakistani population. Asian Pac J Cancer Prev.2014; 15(7): 3035–3039.
5.
Torres-DuránM., Barros-DiosJ.M., Fernández-VillarA., Ruano-RaviñaA.Residential radon and lung cancer in never smokers. A systematic review. Cancer Lett.2014; 345(1): 21–26.
6.
SchillerJ.H., HarringtonD., BelaniC.P.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med.2002; 346(2): 92–98.
7.
StrangeR.C., FryerA.A.The glutathione S-transferases: influence of polymorphism on cancer susceptibility. IARC Sci Publ.1999; (148): 231–249.
8.
HayesJ.D., PulfordD.J.The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol.1995; 30(6): 445–600.
9.
StrangeR.C., SpiteriM.A., RamachandranS., FryerA.A.Glutathione-S-transferase family of enzymes. Mutat Res.2001; 482(1-2): 21–26.
10.
KasthurinaiduS.P., RamasamyT., AyyavooJ., DaveD.K., AdrojaD.A.GST M1-T1 null Allele Frequency Patterns in Geographically Assorted Human Populations: A Phylogenetic Approach. Grolmusz V, ed. PLoS ONE2015; 10(4): e0118660.
11.
YangP., EbbertJ.O., SunZ., WeinshilboumR.M.Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol.2006; 24(11): 1761–1769.
12.
JiaW., SunJ.Y., JiaK.Y., LiuX.C.Role of GSTM1, GSTT1, and GSTP1 Ile105Val gene polymorphisms in the response to chemotherapy and overall survival of advanced non-small cell lung cancer, Genet Mol Res.2016: 23; 15(3).
13.
XiaoH.L., YangZ.T., HanF., WeiH.X.Association of glutathione S-transferase(GST) genetic polymorphisms with treatment outcome of cisplatin-based chemotherapy for advanced non-small cell lung cancer in a Chinese population. Genet Mol Res2016; 28:15(2).
14.
LiuK., LinQ., DingH., JinY., ChenG.Predictive potential role of GSTs gene polymorphisms in the treatment outcome of advanced non-small cell lung cancer patients. Int J Clin Exp Med.2015; 8(11): 20918–20924.
15.
WuG., JiangB., LiuX., ShenY., YangS.Association of GSTs gene polymorphisms with treatment outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy. Int J Clin Exp Pathol.2015; 8(10): 13346–13352.
16.
Ruano-RavinaA., García-BasteiroA.L., Pérez-RíosM., Gómez-MosqueraA., Cerdeira-CaramésS., Barros-DiosJ.M.Lung cancer survival and deletion of GSTM1 and GSTT1 genes. A case-series from Spain. Tumori.2013; 99(4): 445–451.
17.
LiW., YueW., ZhangL.Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients. Lung.2012; 190(1): 91–98.
18.
JoergerM., BurgersS.A., BaasP.Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer.2012; 118(9): 2466–2475.
19.
AdaA.O.C.C., KunakS., HancerF.CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. Neoplasma.2010; 57(6): 512–521.
20.
MoyerA.M., SunZ., BatzlerA.J.Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev.2010; 19(3): 811–821.
SreejaL., SyamalaV., HariharanS.Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients. J Exp Ther Oncol.2008; 7(1): 73–85.
23.
HaqueA.K., AuW., Cajas-SalazarN.CYP2E1 polymorphism, cigarette smoking, p53 expression, and survival in non-small cell lung cancer: a long term follow-up study. Appl Immunohistochem Mol Morphol.2004; 12(4): 315–322.
24.
SweeneyC., Nazar-StewartV., StapletonP.L., EatonD.L., VaughanT.L.Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev.2003; 12(6): 527–533.
25.
YangP., YokomizoA., TazelaarH.D.Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. Lung Cancer.2002; 35(3): 221–229.
26.
GotoI., YonedaS., YamamotoM., KawajiriK.Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res1996; 15: 56(16): 3725–30.
27.
PrzygodzkiR.M., BennettW.P., GuineeD.G.J.Jr.p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. Pharmacogenetics.1998; 8(6): 503–511.
